WorldCat Identities

Allison, James P.

Overview
Works: 28 works in 46 publications in 1 language and 515 library holdings
Genres: Conference papers and proceedings  Academic theses 
Roles: Editor, Speaker, Author, Interviewee, pan, Other
Publication Timeline
.
Most widely held works by James P Allison
Hybridomas and cellular immortality by Baldwin H Tom( Book )

6 editions published in 1983 in English and held by 223 WorldCat member libraries worldwide

The ability to "immortalize" immunologically-useful cells by hybridization with a unique cancer cell has revolutionized serological studies and has revealed new potential applications in all fields of biological sciences. This volume presents the studies from a highly successful national symposium on Hybridomas and Cellular Immortality held November 1981 in Houston, Texas. The individual chapters exhibit the diversity of topics discussed during the meeting. These include emphasis on the origin of antibody diversity, Band T lymphocyte differentiation, applications of monoclonal antibodies in studies of histocompatibility, tumor, and viral antigens, plus the use of somatic cell hybridizations for studying T cell products. Three papers focus on the emerging methodologies of in vitro primary immunizations for both humoral and cell-mediated immunities, relevant for coupling with hybridoma technology. There is a useful mix of general (methods) and specific (applications) chapters. A unique aspect of the book is the presentation of both recent research findings with concise descriptions of the state of the art methodologies. It is anticipated that this work will be of interest to a wide audience of practioners in biomedical research. Hopefully, the information contained will foster new and imagi­ native ideas in hybridoma applications. Baldwin H. Tom, Ph.D. James P. Allison, Ph.D. vii CONTENTS PART L INTRODUCTION TO HYBRIDOMAS 1 Somatic Cell Hybrids and Hybridomas Baldwin H. Tom 3 1. Somatic Cell Hybrids 8 Hybridomas. • • • • • 2
Cancer immunotherapy by James P Allison( )

7 editions published in 2006 in English and held by 212 WorldCat member libraries worldwide

"For some time immunotherapy has been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, the approach needs considerable refinement. Whilst some programmes are looking to increase the understanding of molecular and cellular mechanisms underlying the stimulation of antitumor immunity, others are trying to find the most appropriate clinical setting that will reveal the role of the immune system in combating cancer. Among the most important discoveries have been tumor-specific antigens. This thematic volume highlights some key issues and discusses where they may move forward. It has been put together by two leading cancer immunotherapists from two eminent institutions that focus on cancer research."--BOOK JACKET
Checkpoint blockade in cancer immunotherapy by James P Allison( Visual )

2 editions published in 2007 in English and held by 51 WorldCat member libraries worldwide

Audio-visual presentation : Activation of naive T-cells ; CD28 and CTLA-4 ; Differential regulation of T-cell responses ; Responding repertoire ; Biological role of CTLA-4 ; Tumor-specific immune responses ; Treg activity ; CTLA-4/GVax ; Immunotherapies ; Conventional therapies ; Ipilumumab ; Clinical studies: melanoma ; Reversible immune mediated toxicity
Tumor immunology by American Association of Immunologists( Visual )

2 editions published in 1997 in English and held by 3 WorldCat member libraries worldwide

Presents the immunology of cancer, and immunological therapies for treating cancer
Marian E. Koshland, 1921-1997 : retrospectives on a life in academic science, family, and community activities( )

1 edition published in 2003 in English and held by 3 WorldCat member libraries worldwide

Retrospective interviews about Marian Elliott Koshland (1921-1997) with eight individuals--friends, family and colleagues. Koshland's support of immunology as a distinct field, role in the reorganization of biology at the University of California, Berkeley; membership and support of the Haverford College board of directors, National Immunology Society, National Science Foundation, Exploratorium board of directors, Jane Coffins Memorial Fund, Marian E. Koshland Integrated Science Center, Graduate Affairs Office in the Department of Molecular and Cellular Biology, Lawrence Hall of Science, National Academy of Sciences, National Institute of Health, Bay Area Immunology Club, American Association of Immunologists; work in the Brookhaven National Laboratory; women in science; husband Dr. Daniel Koshland, Jr., and children; balancing family life and research responsibilities
Advances in immunology( Book )

3 editions published in 2006 in English and held by 3 WorldCat member libraries worldwide

The effects of forestry on the chemistry of poorly buffered streams in Connemara by James P Allison( Book )

2 editions published in 1990 in English and held by 2 WorldCat member libraries worldwide

Gamma delta T cells( Book )

1 edition published in 1991 in Undetermined and held by 2 WorldCat member libraries worldwide

Cancer Immunotherapy( )

2 editions published in 2006 in English and held by 2 WorldCat member libraries worldwide

Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity by Maher G Nawaf( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Although strategies that block FOXP3-dependent regulatory T cell function (CTLA4 blockade) and the inhibitory receptor PD1 have shown great promise in promoting antitumor immune responses in humans, their widespread implementation for cancer immunotherapy has been hampered by significant off-target autoimmune side effects that can be lethal. Our work has shown that absence of OX40 and CD30 costimulatory signals prevents CD4 T cell-driven autoimmunity in Foxp3-deficient mice, suggesting a novel way to block these side effects. In this study, we show that excellent antitumor CD8 T cell responses can be achieved in Foxp3(KO) mice deficient in OX40 and CD30 signals, particularly in the presence of concurrent PD1 blockade. Furthermore, excellent antitumor immune responses can also be achieved using combinations of Abs that block CTLA4, PD1, OX40, and CD30 ligands, without CD4 T cell-driven autoimmunity. By dissociating autoimmune side effects from anticancer immune responses, this potentially shifts this antitumor approach to patients with far less advanced disease
Checkpoint blockade in cancer immunotherapy by James P Allison( )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

Audio-visual presentation: Activation of naive T-cells -- CD28 and CTLA-4 -- Differential regulation of T-cell responses -- Responding repertoire -- Biological role of CTLA-4 -- Tumor-specific immune responses -- Treg activity -- CTLA-4/GVax -- Immunotherapies -- Conventional therapies -- Ipilumumab -- Clinical studies: melanoma -- Reversible immune mediated toxicity
[Faculty series] by Ill.) Knox College (Galesburg( )

in English and held by 1 WorldCat member library worldwide

Cancer Immunology and Immunotherapy : from Conception to Delivery by Annual CEI Symposia( Visual )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

(CIT): This two-day national symposium addresses recent advances in the field and should be an exciting forum for discussion and debate on the current understanding of cancer and immunology and immunotherapy. Sessions will include: -Fundamentals of CAR-based Therapies I & II -The Basis of Tumor Recognition -Checkpoint Modulators -Fundamental Biology of T Lymphocytes -Cancer Vaccines and Their Context
Cancer classification using the Immunoscore a worldwide task force by Jerome Galon( )

1 edition published in 2012 in English and held by 1 WorldCat member library worldwide

Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the ` Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)
New insights into negative costimulation and its manipulation in tumor immunotherapy by James P Allison( Visual )

1 edition published in 2002 in English and held by 1 WorldCat member library worldwide

(CIT): The Immunology Interest Group (IIG) organizes activities designed to promote information exchange and interactions among NIH scientists interested in the field of immunology, broadly defined. Interactions are facilitated via weekly meetings on current topics as well as an annual Immunology Retreat. For more information, visit The Immunology Interest Group
[Gamma symbol] [delta symbol] T cells( Book )

1 edition published in 1991 in English and held by 1 WorldCat member library worldwide

Human DR(Ia-like) antigens : biological and molecular profile( )

1 edition published in 1978 in English and held by 1 WorldCat member library worldwide

[Gamma][delta] T cells( Book )

1 edition published in 1991 in English and held by 1 WorldCat member library worldwide

Checkpoint blockade in cancer immunotherapy by James P Allison( )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

Audio-visual presentation : Activation of naive T-cells - CD28 and CTLA-4 - Differential regulation of T-cell responses - Responding repertoire - Biological role of CTLA-4 - Tumor-specific immune responses - Treg activity - CTLA-4/GVax - Immunotherapies - Conventional therapies - Ipilumumab - Clinical studies: melanoma - Reversible immune mediated toxicity
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.60 (from 0.23 for [Faculty s ... to 0.98 for Human DR(I ...)

Cancer immunotherapy Advances in immunology Cancer Immunotherapy
Covers
Advances in immunologyCancer Immunotherapy
Alternative Names
Allison, Jim (Jim P.)

Iacobus Allison

James Allison americký imunolog

James P. Allison Amerikaans immunoloog

James P. Allison amerikansk immunolog

James P. Allison certificate natural

James P. Allison immunologiste américain

James P. Allison immunologo e docente universitario statunitense

James P. Allison US-amerikanischer Immunologe

James Patrick Allison

Джеймс Алисън

Джеймс Еллісон американський імунолог, нобелівський лауреат (2018)

Эллисон, Джеймс

Эллисон, Джеймс американский иммунолог, лауреат Нобелевской премии по медицине и физиологии за 2018 год

Џејмс Елисон американски имунолог и нобеловец

ג'יימס אליסון

جيمس أليسون عالم مناعة أمريكي

جیمز پی. آلیسون

जेम्स पी एलिसन

জেমছ পি. এলিচন

জেমস পি. এলিসন

ଜେମସ ପି. ଆଲିସନ

சேம்சு ஆலிசன்

ജെയിംസ് പി ആലിസൺ

제임스 P. 앨리슨 미국의 면역학자

ジェームズ・P・アリソン

詹姆斯·艾利森

Languages
English (36)